Prostate Cancer Recurrence: Genomic Clues.
In the largest genomic analysis of intermediate-risk prostate cancer samples to date, researchers have uncovered a five-element molecular signature that could help pinpoint patients whose disease is likely to recur and metastasize even after surgery or radiotherapy. They hope to develop a prognostic assay from this signature that can be used in the clinic.